Abstract
The liver is the most frequent site of metastases as a result of the portal circulation and up to 60%-80% of patients with a history of colorectal carcinoma, pancreas carcinoma, breast cancer or other tumor types will develop metastases within the liver during the follow-up period [1]. There is no doubt that surgical resection of these metastases is the only potential curative option for these patients and is therefore considered as gold standard. However, due to anatomic or technical reasons or simple inoperability, only 20% of patients are suitable candidates for resection
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278
Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radio-frequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825; discussion 825-817
Goldberg RM, Hurwitz HI, Fuchs CS (2006) The role of targeted therapy in the treatment of colorectal cancer. Clin Adv Hematol Oncol 4 Suppl 17:1–12
Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40:225–235
Lewandowski RJ, Thurston KG, Goin JE et al (2005) 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16:1641–1651
Murthy R, Nunez R, Szklaruk J et al (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographies 25 Suppl l:S41–55
Salem R, Lewandowski RJ, Atassi B et al (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627–1639
Goin JE, Salem R, Carr BI et al (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16:205–213
Goin JE, Salem R, Carr BI et al (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 16:195–203
Salem R, Lewandowski R, Roberts C et al (2004) Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 15:335–345
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hoffmann, RT., Jakobs, T.F., Reiser, M.F. (2008). Identification of Candidates and Selection Criteria. In: Bilbao, J.I., Reiser, M.F. (eds) Liver Radioembolization with 90Y Microspheres. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-35423-9_2
Download citation
DOI: https://doi.org/10.1007/978-3-540-35423-9_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-35421-5
Online ISBN: 978-3-540-35423-9
eBook Packages: MedicineMedicine (R0)